Brokers Offer Predictions for Kura Oncology FY2025 Earnings

Kura Oncology, Inc. (NASDAQ:KURA) – Equities researchers at Brookline Capital Management cut their FY2025 earnings estimates for Kura Oncology in a report released on Tuesday, November 4th. Brookline Capital Management analyst L. Cann now expects that the company will post earnings per share of ($2.74) for the year, down from their previous forecast of ($2.54). The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share. Brookline Capital Management also issued estimates for Kura Oncology’s Q4 2025 earnings at ($0.48) EPS, FY2026 earnings at ($0.42) EPS, FY2028 earnings at $5.78 EPS and FY2029 earnings at $12.08 EPS.

KURA has been the subject of several other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kura Oncology in a research note on Wednesday, October 8th. Guggenheim assumed coverage on shares of Kura Oncology in a research note on Thursday, September 4th. They set a “neutral” rating for the company. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Kura Oncology in a research report on Monday, October 20th. JMP Securities reaffirmed a “market outperform” rating and issued a $24.00 price objective on shares of Kura Oncology in a report on Monday, October 20th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $36.00 price objective on shares of Kura Oncology in a report on Monday, October 20th. Ten equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $24.67.

Kura Oncology Trading Down 0.2%

NASDAQ:KURA opened at $9.94 on Thursday. Kura Oncology has a 12 month low of $5.41 and a 12 month high of $19.73. The firm has a fifty day simple moving average of $9.12 and a 200-day simple moving average of $7.28. The company has a current ratio of 6.16, a quick ratio of 6.16 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $862.76 million, a P/E ratio of -4.01 and a beta of 0.35.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Tuesday, November 4th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.28). Kura Oncology had a negative net margin of 208.48% and a negative return on equity of 60.05%. The firm had revenue of $20.75 million during the quarter, compared to analyst estimates of $17.48 million.

Insider Activity

In other Kura Oncology news, CEO Troy Edward Wilson purchased 50,000 shares of the stock in a transaction that occurred on Monday, September 8th. The shares were purchased at an average cost of $8.20 per share, for a total transaction of $410,000.00. Following the completion of the transaction, the chief executive officer owned 100,968 shares of the company’s stock, valued at $827,937.60. The trade was a 98.10% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Kathleen Ford sold 6,892 shares of the business’s stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $8.94, for a total transaction of $61,614.48. Following the transaction, the chief operating officer owned 63,375 shares in the company, valued at $566,572.50. The trade was a 9.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 78,058 shares of company stock valued at $697,839 in the last ninety days. 6.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Kura Oncology

Several institutional investors and hedge funds have recently bought and sold shares of the company. E Fund Management Co. Ltd. boosted its holdings in Kura Oncology by 18.9% in the 1st quarter. E Fund Management Co. Ltd. now owns 12,252 shares of the company’s stock valued at $81,000 after purchasing an additional 1,951 shares during the last quarter. Arizona State Retirement System boosted its holdings in Kura Oncology by 15.8% in the 3rd quarter. Arizona State Retirement System now owns 20,481 shares of the company’s stock valued at $181,000 after purchasing an additional 2,802 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Kura Oncology by 10.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 30,273 shares of the company’s stock valued at $175,000 after purchasing an additional 2,976 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Kura Oncology by 6.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 50,008 shares of the company’s stock valued at $333,000 after purchasing an additional 2,977 shares during the last quarter. Finally, Pallas Capital Advisors LLC lifted its holdings in shares of Kura Oncology by 32.2% in the 2nd quarter. Pallas Capital Advisors LLC now owns 13,304 shares of the company’s stock worth $77,000 after acquiring an additional 3,241 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.